InterMune (nasdaq)ITMN Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Secret_Agent_Man who started this subject	2/16/2001 11:54:24 AM
From: IRWIN JAMES FRANKEL	Read Replies (1) of 508

ITMN CC notes: - IPF PIII enrolling at 40 of 53 sites - 71 of 260 patients enrolled for IPF - will start PIII for ovarian cancer 2H01 - will start PII for cystic fibrosis 2H01 - will be presenting at symposiums for pulmonary and cancer - has 8 MD's on staff looking at other uses of Actimunne - 100% of growth Q over Q is coming form off lable use - combo treatment with Amphotec is very exciting prospect - hope to be able to file NDA for IPF in late 2002 or early 2003 - expect to get priority review for IPF due to lack of treatments available - 84% of 3rd party payers are covering Actimunne treatment - repeated mid 01 as date to finish enrolling IPF - looking at other fibrotic disease possibilities in liver and kidney - negative cash flows 01 and 02 $30M, 03 $15-25M - cash $194M, adequate for next several years - good participation in the CC The stock is cheap at 33 today. IMO :-) ij

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next